# Novel Therapies Sector

Canonical URL: https://biopharmsignal.com/sector/novel-therapies

Novel Therapies groups companies pursuing newer or less established treatment strategies that fall outside traditional small-molecule or standard biologic categories. It is a broad innovation bucket that often overlaps with cell therapy, gene therapy, and next-generation immunotherapy.

Companies currently grouped under Novel Therapies: 5

## Recent Sector News

- 2026-08-13 05:00 EST — PHAR — [Pharming announces commercial launch of Joenja (leniolisib) in Japan for adult and pediatric patients with APDS aged 4 and older](https://biopharmsignal.com/news/PHAR/pharming-announces-commercial-launch-of-joenja-leniolisib-in-japan-for-adult-and-15d022ed) — Source: Pharming Group
- 2026-08-04 06:00 EST — PHAR — [Pharming Group to participate in Canaccord Genuity 46th Annual Growth Conference](https://biopharmsignal.com/news/PHAR/pharming-group-to-participate-in-canaccord-genuity-46th-annual-growth-conference-89bea5c1) — Source: Pharming Group
- 2026-07-30 05:00 EST — PHAR — [Pharming reports second quarter and first half 2026 financial results and revises year-end guidance; strong Joenja momentum and near-term clinical readouts to support broader therapeutic use](https://biopharmsignal.com/news/PHAR/pharming-reports-second-quarter-and-first-half-2026-financial-results-and-revise-5218552c) — Source: Pharming Group
- 2026-07-16 06:00 EST — PHAR — [Pharming Group to report second quarter and first half 2026 financial results and provide business update on July 30](https://biopharmsignal.com/news/PHAR/pharming-group-to-report-second-quarter-and-first-half-2026-financial-results-an-f222ee56) — Source: Pharming Group
- 2026-06-04 05:00 EST — PHAR — [Pharming announces U.S. FDA acceptance of sNDA resubmission for Joenja® (leniolisib) to treat children aged 4 to 11 years with APDS](https://biopharmsignal.com/news/PHAR/pharming-announces-u-s-fda-acceptance-of-snda-resubmission-for-joenja-leniolisib-5cf3429e) — Source: Pharming Group
- 2026-06-02 06:00 EST — PHAR — [Pharming Group to participate in Fireside Chat at  2026 Jefferies Global Healthcare Conference in New York](https://biopharmsignal.com/news/PHAR/pharming-group-to-participate-in-fireside-chat-at-2026-jefferies-global-healthca-b0957d70) — Source: Pharming Group
- 2026-05-28 14:40 EST — PHAR — [Pharming Group announces results of 2026 Annual General Meeting of Shareholders](https://biopharmsignal.com/news/PHAR/pharming-group-announces-results-of-2026-annual-general-meeting-of-shareholders-5f53ccfa) — Source: Pharming Group
- 2026-05-22 19:30 EST — PHAR — [European Commission grants marketing authorization to Pharming’s Joenja® (leniolisib) – the first approved treatment for APDS in the European Union](https://biopharmsignal.com/news/PHAR/european-commission-grants-marketing-authorization-to-pharming-s-joenja-leniolis-2d21c32e) — Source: Pharming Group
- 2026-05-07 05:05 EST — PHAR — [Pharming Group announces presentations at CIS 2026 Annual Meeting, including leniolisib pediatric data in APDS and clinical experience in CVID and related disorders](https://biopharmsignal.com/news/PHAR/pharming-group-announces-presentations-at-cis-2026-annual-meeting-including-leni-d8b2c6d4) — Source: Pharming Group
- 2026-05-07 05:00 EST — PHAR — [Pharming Group reports first quarter 2026 financial results; on track for Joenja® U.S. pediatric label expansion and launches in Japan and Europe in 2026](https://biopharmsignal.com/news/PHAR/pharming-group-reports-first-quarter-2026-financial-results-on-track-for-joenja--a75d33bb) — Source: Pharming Group
- 2026-04-23 06:00 EST — PHAR — [Pharming Group to report first quarter 2026 financial results and provide business update on May 7](https://biopharmsignal.com/news/PHAR/pharming-group-to-report-first-quarter-2026-financial-results-and-provide-busine-acfc5345) — Source: Pharming Group
- 2026-04-16 06:00 EST — PHAR — [Pharming Group announces the 2026 Annual General Meeting of Shareholders](https://biopharmsignal.com/news/PHAR/pharming-group-announces-the-2026-annual-general-meeting-of-shareholders-0073995c) — Source: Pharming Group
- 2026-04-07 06:00 EST — PHAR — [Pharming Group to participate in April investor conferences](https://biopharmsignal.com/news/PHAR/pharming-group-to-participate-in-april-investor-conferences-3517e32b) — Source: Pharming Group
- 2026-04-02 05:00 EST — PHAR — [Pharming Group announces the filing of its 2025 Annual Report and Form 20-F](https://biopharmsignal.com/news/PHAR/pharming-group-announces-the-filing-of-its-2025-annual-report-and-form-20-f-f295da9d) — Source: Pharming Group
- 2026-03-27 06:00 EST — PHAR — [Pharming Group receives positive CHMP opinion for Joenja® (leniolisib) for the treatment of APDS in adult and pediatric patients 12 years and older](https://biopharmsignal.com/news/PHAR/pharming-group-receives-positive-chmp-opinion-for-joenja-leniolisib-for-the-trea-f30b6c03) — Source: Pharming Group
- 2026-03-24 06:00 EST — PHAR — [Pharming Group announces approval of Joenja® (leniolisib) in Japan for the treatment of APDS in patients aged 4 years and older](https://biopharmsignal.com/news/PHAR/pharming-group-announces-approval-of-joenja-leniolisib-in-japan-for-the-treatmen-a044b78d) — Source: Pharming Group
- 2026-03-12 06:00 EST — PHAR — [Pharming Group reports fourth quarter and full year 2025 financial results, delivering strong revenue growth and profitability with positive cash flow](https://biopharmsignal.com/news/PHAR/pharming-group-reports-fourth-quarter-and-full-year-2025-financial-results-deliv-f64bbf34) — Source: Pharming Group
- 2026-02-26 07:00 EST — PHAR — [Pharming Group to report fourth quarter and full year 2025 financial results and provide business update on March 12](https://biopharmsignal.com/news/PHAR/pharming-group-to-report-fourth-quarter-and-full-year-2025-financial-results-and-16bb7c03) — Source: Pharming Group
- 2026-02-17 07:00 EST — PHAR — [Pharming Group to present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference](https://biopharmsignal.com/news/PHAR/pharming-group-to-present-at-the-oppenheimer-36th-annual-healthcare-life-science-e361b462) — Source: Pharming Group
- 2026-02-03 06:00 EST — PHAR — [Pharming Group announces 2026 financial guidance and highlights rare disease pipeline at Investor Day](https://biopharmsignal.com/news/PHAR/pharming-group-announces-2026-financial-guidance-and-highlights-rare-disease-pip-96b038fa) — Source: Pharming Group

## Companies

- [HNSA](https://biopharmsignal.com/company/HNSA) — Hansa Biopharma AB
- [JNJ](https://biopharmsignal.com/company/JNJ) — Johnson & Johnson
- [LNTH](https://biopharmsignal.com/company/LNTH) — Lantheus Holdings, Inc.
- [NVS](https://biopharmsignal.com/company/NVS) — Novartis AG
- [PHAR](https://biopharmsignal.com/company/PHAR) — Pharming Group